Two companies supported by HiTT get outstanding reward.

HiTT celebrates that Barcelona Activa recognizes Qbeast with an award for the best project of high technological impact and Hospital Vall d’Hebron obtains more than 1M€ benefit from the exploitation of a patent license. 

Qbeast is a ‘Big Data’ analysis platform that allows the indexation and visualization of data in a responsive, clear and intuitive way.  

On  February, Barcelona Activa has awarded the Qbeast startup for the best business project with a high technological impact, with an economic contribution of 5.000€, in the framework of the fifth edition of the Preacceleració Program. Qbeast has also obtained an office space in the MediaTIC Incubator. HiTT has pleased worked all along with Qbeast to define its business model and its development path. 

Also in February Hospital Vall d’Hebron has published that Hospital Vall d’Hebron has obtained more than € 1M benefit from the licence of a new treatment for a rare disease, representing the highest economic benefit generated by a state research institute by a patent licence. Doctors Ramon Martí (VHIR) and Michio Hirano (Columbia University) discovered the treatment in 2013. Afterwards, they licenced the patent to Modis Therapeutics, an American company, to develop the therapy. HiTT participated in the evidence review to complete the evidence package of the value dossier of the drug.  

These two successful stories reinforce the idea of Barcelona as a strong life sciences and health HUB articulated around powerful core formed by public hospitals, pharmaceutical companies and research centres with which HiTT has strong and long-standing relationships. 

HiTT is an international market access consultancy with a payer perspective, with offices in Barcelona born in 2013. HiTT focuses its main activity on advising and accompanying institutions, research centres and private companies in the health sector, who wish to develop and implement innovative projects to add value to the health system